On July 3, Dan Ives, the Global Head of Tech Research at Wedbush, appeared on CNBC to suggest that AI will fuel a multi-year tech rally. Ives stated that he believes they are only at the beginning of a golden age for tech. He predicted that tech stocks could rise another 10% to 15% in H2 2025, driven by the unfolding second, third, and fourth derivatives of AI across software, semiconductors, and consumer reports. He emphasized that the AI revolution is the central focus, and its progression is what he believes will propel the NASDAQ to 22,000 or 23,000.
Market movements are rarely linear, and there’s always some kind of downside risk investors should anticipate, even if the long-term trend is upward. Ives acknowledged that such risks, including upcoming trade deals (like the July 9 deadline), Fed actions, and geopolitical events, represent white knuckle moments. However, he viewed these moments as opportunities, consistent with his approach throughout his career, particularly if the fundamental stories are playing out. He reiterated his belief that the tech sector is just starting a 3-year tech bull market, with an anticipated $2 trillion in AI spending over the next 3 years.
That being said, we’re here with a list of the 12 best performing NASDAQ stocks according to analysts.
A closeup of a person’s hand managing a portfolio of stocks on a graphically rich financial app interface.
Methodology
We sifted through the Finviz stock screener to compile a list of the best-performing stocks that are listed on NASDAQ and have a year-to-date performance exceeding 100%. We then selected 12 stocks with an upside potential of over 50%. The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q1 2025, which was sourced from Insider Monkey’s database.
Note: All data was collected on July 7.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
12 Best Performing NASDAQ Stocks According to Analysts
12. DBV Technologies (NASDAQ:DBVT)
Year-to-Date Performance as of July 7: 256.31%
Number of Hedge Fund Holders: 2
Average Upside Potential as of July 7: 58.95%
DBV Technologies (NASDAQ:DBVT) is one of the best-performing NASDAQ stocks according to analysts. On June 25, DBV Technologies announced the screening of the first subject in its COMFORT Toddlers supplemental safety study. The study is evaluating the Viaskin Peanut patch 250 μg in peanut-allergic children between 1 and 3 years old. The announcement was made from Châtillon in France.
The COMFORT Toddlers study is a Phase 3, double-blind, and placebo-controlled/DBPC safety study. It aims to supplement existing safety and efficacy data from the previously completed Phase 3 EPITOPE study, which focused on the same patient population. The study duration is 6 months, followed by an optional 18-month open-label treatment phase. The design will allow for up to 24 or 18 months of active treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively.
DBV Technologies plans to enroll ~480 subjects across 80 to 90 study centers in the US, Canada, Australia, the UK, and Europe. The data generated from the COMFORT Toddlers study is expected to complete the necessary dataset for a Biologics License Application/BLA submission to the FDA. This submission is anticipated in H2 2026 under the Accelerated Approval Pathway, as previously agreed upon with the FDA.
DBV Technologies (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company that researches and develops epicutaneous immunotherapy products in France.
11. Foremost Clean Energy (NASDAQ:FMST)
Year-to-Date Performance as of July 7: 126.09%
Number of Hedge Fund Holders: 2
Average Upside Potential as of July 7: 67.36%
Foremost Clean Energy (NASDAQ:FMST) is one of the best-performing NASDAQ stocks according to analysts. On July 2, Foremost Clean Energy Ltd. announced that drilling is scheduled to commence later this month at its Murphy Lake South Uranium Property. The property is located in the Athabasca Basin region of northern Saskatchewan, which is the focus of a fully permitted and funded first phase of a multi-phase drilling program.
The objective is to test high-priority structural corridors situated adjacent to the LaRocque Lake Conductive Corridor, which is known to host IsoEnergy’s high-grade Hurricane Deposit. The Murphy Lake South Property spans 17,676 acres and is situated approximately 30 kilometers northwest of the McClean Lake mill.
The initial Phase 1 drilling program is expected to involve ~1,500 meters of diamond drilling. The drilling will concentrate on graphitic faults and offset structures identified through previous geophysics and geological interpretations.
Foremost Clean Energy (NASDAQ:FMST) is an exploration-stage company that explores and develops uranium and lithium assets in North America.
10. Palvella Therapeutics Inc. (NASDAQ:PVLA)
Year-to-Date Performance as of July 7: 107.50%
Number of Hedge Fund Holders: 13
Average Upside Potential as of July 7: 96.79%
Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the best-performing NASDAQ stocks according to analysts. On June 23, Palvella Therapeutics announced the successful completion of enrollment for its Phase 3 SELVA trial. The trial is evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs).
The trial exceeded its initial enrollment target of 40 subjects by over 25%, successfully enrolling 51 subjects at leading US vascular anomaly centers. This over-enrollment highlights the significant unmet need for treatments for this serious and lifelong genetic disease, for which no FDA-approved therapies currently exist.
The SELVA trial is a 24-week, Phase 3, single-arm, and baseline-controlled study designed to evaluate once-daily QTORIN rapamycin in individuals aged 3 years and older with microcystic LMs. QTORIN rapamycin has received several significant designations from the FDA for the treatment of microcystic LMs, such as Breakthrough Therapy, Orphan Drug, and Fast Track designations. If approved, QTORIN rapamycin is expected to qualify for 7 years of orphan drug market exclusivity in the US.
Palvella Therapeutics Inc. (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapies to treat patients with serious and rare genetic skin diseases.
9. Neuronetics Inc. (NASDAQ:STIM)
Year-to-Date Performance as of July 7: 109.32%
Number of Hedge Fund Holders: 26
Average Upside Potential as of July 7: 107.72%
Neuronetics Inc. (NASDAQ:STIM) is one of the best-performing NASDAQ stocks according to analysts. On June 10, Neuronetics announced its significant presence at the 13th Annual Clinical TMS Society/CTMSS Meeting and provided an update on Greenbrook’s Personalized Care Trial Program. NeuroStar, which is Neuronetics’ brand, participated as a Silver Sponsor at the CTMSS Meeting, which took place from June 11 to June 14 this year in San Diego, CA.
The company showcased its commitment to clinical innovation by presenting two posters derived from the TrakStar data set, which is the largest real-world outcomes database in Transcranial Magnetic Stimulation/TMS. During the CTMSS Meeting, NeuroStar presented two key data sets. One presentation focused on the largest-to-date analysis of elderly adults (age 70 and older) with Major Depressive Disorder/MDD treated with TMS. The other one provided a retrospective analysis of data from 200 Greenbrook centers, offering a direct comparison of clinical outcomes between NeuroStar’s proprietary Figure-8 coil and Brainsway’s H-coil in the treatment of depression.
NeuroStar also participated in the PULSES Course, a foundational training session for TMS providers, and exhibited at booth #303. Additionally, Neuronetics provided an update on Greenbrook Mental Wellness Centers’ Personalized Care Trial Program. Greenbrook is a wholly-owned subsidiary of Neuronetics and initiated this program to assess the feasibility of using personalized qEEG-informed protocols for delivering TMS therapy with the NeuroStar TMS System.
Neuronetics Inc. (NASDAQ:STIM) provides office treatments for patients with neurohealth disorders in the US and internationally.
8. GH Research (NASDAQ:GHRS)
Year-to-Date Performance as of July 7: 114.36%
Number of Hedge Fund Holders: 12
Average Upside Potential as of July 7: 113.26%
GH Research (NASDAQ:GHRS) is one of the best-performing NASDAQ stocks according to analysts. On June 20, GH Research announced that it had submitted a complete response to the US FDA regarding the clinical hold on its Investigational New Drug/IND Application for GH001. The submission was made ahead of schedule, which showed the company’s commitment to advancing its lead product candidate.
The CEO of GH Research, Dr. Velichka Valcheva, pointed out that the response addressed the FDA’s requests with comprehensive data and completed toxicology studies. GH001 is GH Research’s lead product candidate, which was formulated for mebufotenin (5-methoxy-N,N-dimethyltryptamine or 5-MeO-DMT) administration via a proprietary inhalation approach.
The company believes that GH001 has the potential to transform the treatment of treatment-resistant depression/TRD. This belief is supported by the observed clinical activity in their Phase 2b GH001-TRD-201 trial. In this trial, the primary endpoint was met, showing a significant reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline of -15.5 points compared with placebo on Day 8.
GH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company that develops treatments for depression in the US.
7. Artelo Biosciences Inc. (NASDAQ:ARTL)
Year-to-Date Performance as of July 7: 125.16%
Number of Hedge Fund Holders: 1
Average Upside Potential as of July 7: 151.40%
Artelo Biosciences Inc. (NASDAQ:ARTL) is one of the best-performing NASDAQ stocks according to analysts. On July 7, Artelo Biosciences announced positive preclinical efficacy data for its drug candidate, ART12.11, in a stress-induced depression model. These findings were presented at the 35th Annual International Cannabinoid Research Society/ICRS Symposium, which was held from July 6 to 10 this year, in Bloomington, Indiana.
The preclinical data was presented in a poster titled “ART12.11, A Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Alleviates Stress-Induced Depressive Symptoms,” and showcased ART12.11’s unique dual-action profile. In male rats exposed to chronic stress, a 28-day treatment regimen with ART12.11 reversed behavioral impairments, showing antidepressant-like effects comparable to sertraline (Zoloft), which is a selective serotonin reuptake inhibitor/SSRI. ART12.11 also restored hedonic and social behaviors, such as sucrose preference and social motivation, to near-baseline levels, similar to sertraline.
ART12.11 has superior cognitive restoration. Unlike sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, making it a differentiated therapeutic profile. This positions it as a potential next-generation treatment for depression and anxiety.
Artelo Biosciences Inc. (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company that develops and commercializes therapeutics that target lipid-signaling pathways in the US.
6. CervoMed Inc. (NASDAQ:CRVO)
Year-to-Date Performance as of July 7: 150.85%
Number of Hedge Fund Holders: 1
Average Upside Potential as of July 7: 155.54%
CervoMed Inc. (NASDAQ:CRVO) is one of the best-performing NASDAQ stocks according to analysts. On June 10, CervoMed announced a significant addition to its senior leadership team. Dr. Marco Verwijs, PhD, joined CervoMed in June this year as Executive Vice President, Technical Operations. The strategic hire is intended to support the company’s Chemistry, Manufacturing, and Controls/CMC division.
This hire will also support the advancement of neflamapimod through Phase 3 testing and preparation for commercial manufacturing, as Dr. Verwijs brings extensive experience in drug development, spanning from the pre-clinical stage through NDA submissions and commercial launch. Before joining CervoMed, he served as CTO at Adipo Therapeutics. His expertise includes a particular focus on drug product and process development, scale-up, and validation, as well as overseeing supply chain and quality assurance.
Neflamapimod is an investigational and orally administered small-molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. It is being developed to potentially treat synaptic dysfunction, which is a reversible aspect of the neurodegenerative processes underlying DLB and other major neurological disorders.
CervoMed Inc. (NASDAQ:CRVO) is a clinical-stage biotechnology company that develops and commercializes treatments for age-related neurologic disorders.
5. The Oncology Institute Inc. (NASDAQ:TOI)
Year-to-Date Performance as of July 7: 728.48%
Number of Hedge Fund Holders: 12
Average Upside Potential as of July 7: 173.44%
The Oncology Institute Inc. (NASDAQ:TOI) is one of the best-performing NASDAQ stocks according to analysts. On June 30, the Oncology Institute announced a partnership with SilverSummit Healthplan. Effective July 1, TOI will serve as the exclusive oncology provider for 80,000+ Medicaid members associated with SilverSummit Healthplan in Nevada.
The collaboration is set to enhance access to advanced cancer care and high-level services for the Medicaid population in the Las Vegas area. SilverSummit Healthplan members now have access to The Oncology Institute’s comprehensive cancer care at 3 distinct locations in Nevada.
The Oncology Institute supports 120+ employed clinicians and 700+ teammates across 70+ clinic locations. The CEO of The Oncology Institute, Daniel Virnich, MD, particularly highlighted TOI’s proven track record of delivering excellent care to Medicaid patients in other regions.
The Oncology Institute Inc. (NASDAQ:TOI) is an oncology company that provides various medical oncology services in the US.
4. I-Mab (NASDAQ:IMAB)
Year-to-Date Performance as of July 7: 145.88%
Number of Hedge Fund Holders: 5
Average Upside Potential as of July 7: 187.08%
I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona.
Givastomig, which is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) and 4-1BB, was evaluated in combination with nivolumab (an anti-PD-1 checkpoint inhibitor) and mFOLFOX6 (a chemotherapy regimen including leucovorin calcium, fluorouracil, and oxaliplatin) as a first-line (1L) therapy for patients with CLDN18.2-positive gastric cancers.
The primary endpoint of the study was safety, and givastomig showed favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 treatment-related adverse event/TRAE for increased liver enzymes.
I-Mab (NASDAQ:IMAB) is a biotech company that develops immuno-oncology agents for the treatment of cancer in the US.
3. Microbot Medical Inc. (NASDAQ: MBOT)
Year-to-Date Performance as of July 7: 124.11%
Number of Hedge Fund Holders: 1
Average Upside Potential as of July 7: 258.57%
Microbot Medical Inc. (NASDAQ:MBOT) is one of the best-performing NASDAQ stocks according to analysts. On June 17, Microbot Medical announced that it had been granted a patent in China by the China National Intellectual Property Administration/CNIPA.
The patent covers the robotic manipulation of a surgical tool handle and is a step in the company’s global intellectual property/IP expansion strategy. LIBERTY System now includes 9 patents granted globally and 59 patent applications pending. The LIBERTY system is a single-use and fully disposable endovascular robotic system for assisting surgeons in performing minimally invasive procedures within blood vessels.
The patent portfolio protects the capabilities of the LIBERTY System. Microbot Medical’s focus remains on the US market, where it is preparing for the anticipated commercial launch of the LIBERTY Endovascular Robotic System in Q3 2025.
Microbot Medical Inc. (NASDAQ:MBOT) is a clinical-stage medical device company that researches, designs, and develops robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the US.
2. Atai Life Sciences (NASDAQ:ATAI)
Year-to-Date Performance as of July 7: 106.77%
Number of Hedge Fund Holders: 14
Average Upside Potential as of July 7: 263.64%
Atai Life Sciences (NASDAQ:ATAI) is one of the best-performing NASDAQ stocks according to analysts. On July 1, Atai Life Sciences and Beckley Psytech Limited jointly announced positive topline results from the 8-week, quadruple-masked, dose-finding, core stage of their Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 in patients with treatment-resistant depression/TRD.
BPL-003 is Beckley Psytech’s patent-protected intranasal formulation of mebufotenin (5-MeO-DMT) benzoate, which is administered via a previously approved nasal spray device. The study enrolled 193 patients with moderate-to-severe TRD across 38 sites in 6 countries, including the US, and successfully met its primary and all key secondary endpoints.
Follow-up in the 8-week open-label extension/OLE stage of the study is ongoing, with 85% of eligible subjects from the core stage having enrolled. The OLE study is designed to evaluate the safety and efficacy of a second 12 mg dose of BPL-003 administered 8 weeks after the core study dosing. Data from the OLE study are expected in Q3 2025 and will provide further insights into the safety, tolerability, and durability of repeat dosing.
Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the US, Germany, and Canada. Beckley Psytech Ltd. is a private biopharmaceutical company.
1. VivoPower International (NASDAQ:VVPR)
Year-to-Date Performance as of July 7: 332.33%
Number of Hedge Fund Holders: 1
Average Upside Potential as of July 7: 769.57%
VivoPower International (NASDAQ:VVPR) is one of the best-performing NASDAQ stocks according to analysts. On June 11, VivoPower announced a definitive partnership with Flare. The collaboration aims to generate yield on VivoPower’s digital assets, beginning with an initial deployment of $100 million in XRP. The move serves as a validation of the XRP ecosystem’s utility for institutional treasury management.
The XRP ecosystem is a digital payment network built around the XRP Ledger/XRPL. VivoPower will generate yield through protocols on the Flare Network, such as Firelight, and will reinvest this income directly back into XRP holdings.
The partnership also delivers the first institutional-scale validation of Flare’s FAssets system, which establishes it as a programmable utility layer for the XRP ecosystem. FAssets is a non-custodial protocol that allows XRP to be used in smart contract applications while preserving its native security model.
VivoPower International (NASDAQ:VVPR) provides energy solutions for customized & ruggedized fleet applications, battery & microgrids, and solar and critical power technology & services. Flare is a next-gen Layer 1 blockchain designed to connect decentralized systems with real-world utility through secure and data-rich interoperability.
While we acknowledge the potential of VVPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VVPR and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
